HZNP News and Press, Horizon Therapeutics Public Limited Company From 09/19/22

– Meeting plenary session to feature 12-Month data from MIRROR randomized controlled trial of KRYSTEXXA ® (pegloticase) injection with methotrexate – Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for a series of data presentations o...

-- Novel Program Supports Student Education and Future Careers in Patient Advocacy -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the University of Notre Dame’s Patient Advocacy Initiative in the ...

-- Month 6 data showed a greater than 30 percentage-point increase in efficacy, and a significant reduction in infusion reactions from 31% to 4% -- -- Publication of data follows U.S. Food and Drug Administration (FDA) approval of expanded labeling of KRYSTEXXA co-administered...

-- Annual observance aims to raise awareness of blindness and vision impairment as a major global public health and development issue -- Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with World Sight Day organizers IAPB to challenge five million people globally to pl...

Horizon Therapeutics ( NASDAQ: HZNP ) said on Monday its Phase 2 trial testing its drug, dazodalibep, to treat Sjögren’s syndrome met the primary endpoint in patients with moderate-to-high systemic disease. The company said at week 24, patients treated with daz...

- The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 trial evaluating dazodalibep for...

Horizon Therapeutics ( NASDAQ: HZNP ) announced Friday that it has received Board's approval to repurchase up to $500M of its shares. "Our strong balance sheet and cash generation gives us the flexibility to opportunistically repurchase shares while maintaining ample capit...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company’s ordinary shares. “This share repurchase program reinforces the confidence we have in our strategy and our commitment to ...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2022 list in the large company category. This is the sixth consecutive year Horizon has been named to the list and the company’s third time ranking No. ...

Summary Shares of Horizon Therapeutics are down 50% from last year's highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at current levels, but Tepezza remains well-positioned for long-term growth...